Build status - In Progress

TrialX API NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).

Study on Chemotherapy for Colon Cancer

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Online study

This study investigates colon cancer treatment after surgery. The purpose is to understand how chemotherapy affects patients with remaining disease.

The focus is on evaluating the effectiveness of chemotherapy regimens in patients with detectable cancer DNA after surgery.

  • Who can participate: Eligibility criteria are yet to be determined.
  • Study details: Participants will receive chemotherapy to assess its impact on colon cancer.
Updated on 20 Mar 2026. Study ID: 89-57152
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator